In-vitro immunosuppression of canine T-lymphocyte-specific proliferation with dexamethasone, cyclosporine, and the active metabolites of azathioprine and leflunomide in a flow-cytometric assay

Canadian Journal of Veterinary Research

Volumn 78, Issue 3, 2014, Pages 168-175

  Nafe, Laura A ^a,b   Dodam, John R ^a   Reinero, Carol R ^a  

^a UNIVERSITY OF MISSOURI   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CD5 ANTIGEN; CONCANAVALIN A; CYCLOSPORIN; DEXAMETHASONE; LEFLUNOMIDE; PROPIDIUM IODIDE; ANILINE DERIVATIVE; HYDROXYBUTYRIC ACID; IMMUNOSUPPRESSIVE AGENT; ISOXAZOLE DERIVATIVE; MERCAPTOPURINE; TERIFLUNOMIDE;

ANIMAL CELL; ARTICLE; CELL PROLIFERATION; CELL VIABILITY; DENSITY GRADIENT CENTRIFUGATION; FLOW CYTOMETRY; FLUOROCHROME STAINING; IC 50; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTE PROLIFERATION; METABOLITE; NONHUMAN; ANIMAL; CYTOLOGY; DOG; DRUG EFFECTS; IMMUNOLOGY; METABOLISM; PHYSIOLOGY; T LYMPHOCYTE;

6-MERCAPTOPURINE; ANILINE COMPOUNDS; ANIMALS; AZATHIOPRINE; CELL PROLIFERATION; CYCLOSPORINE; DEXAMETHASONE; DOGS; FLOW CYTOMETRY; HYDROXYBUTYRATES; IMMUNOSUPPRESSIVE AGENTS; ISOXAZOLES; T-LYMPHOCYTES;

EID: 84903530920     PISSN: 08309000     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. McCullough S. Immune-mediated hemolytic anemia: Understanding the nemesis. Vet Clin North Am Small Anim Pract 2003;33:1295-1315.
2. Bianco D, Armstrong PJ, Washabau RJ. Prospective, randomized, double-blinded, placebo-controlled study of human intravenous immunoglobulin for the acute management of presumptive primary immune-mediated thrombocytopenia in dogs. J Vet Intern Med 2009;23:1071-1078.
3. Kidd L, Mackman N. Prothrombotic mechanisms and anticoagulant therapy in dogs with immune-mediated hemolytic anemia. J Vet Emerg Crit Care 2013;23:3-13.
4. Grundy SA, Barton C. Influence of drug treatment on survival of dogs with immune-mediated hemolytic anemia: 88 cases (1989-1999). J Am Vet Med Assoc 2001;218:543-546.
5. Piek CJ, Junius G, Dekker A, Schrauwen E, Slappendel RJ, Teske E. Idiopathic immune-mediated hemolytic anemia: Treatment outcome and prognostic factors in 149 dogs. J Vet Intern Med 2008;22:366-373.
6. Reimer ME, Troy GC, Warnick LD. Immune-mediated hemolytic anemia: 70 cases (1988-1996). J Am Anim Hosp Assoc 1999; 35:384-391.
7. Putsche JC, Kohn B. Primary immune-mediated thrombocytopenia in 30 dogs (1997-2003). J Am Anim Hosp Assoc 2008;44: 250-257.
8. Burgess K, Moore A, Rand W, Cotter SM. Treatment of immunemediated hemolytic anemia in dogs with cyclophosphamide. J Vet Intern Med 2000;14:456-462.
9. Weinkle TK, Center SA, Randolph JF, Warner KL, Barr SC, Erb HN. Evaluation of prognostic factors, survival rates, and treatment protocols for immune-mediated hemolytic anemia in dogs: 151 cases (1993-2002). J Am Vet Med Assoc 2005;226: 1869-1880.
10. Dambin C, Klupp J, Morris R. Pharmacodynamics of immunosuppressive drugs. Curr Opin Immunol 2000;12:557-562.
11. Archer TM, Fellman CL, Stokes JV, et al. Pharmacodynamic monitoring of canine T-cell cytokine responses to oral cyclosporine. J Vet Intern Med 2011;25:1391-1397.
12. Fellman CL, Stokes JV, Archer TM, Pinchuk LM, Lunsford KV, Mackin AJ. Cyclosporine A affects the in vitro expression of T cell activation-related molecules and cytokines in dogs. Vet Immunol Immunopathol 2011;140:175-180. Epub 2010 Dec 4.
13. Day MJ. Antigen specificity in canine autoimmune haemolytic anaemia. Vet Immunol Immunopathol 1999;69:215-224.
14. Abbas AK, Lichtman AH, and Pillai S. Cellular and Molecular Immunology. 6th ed. Philadelphia, Pennsylvania: Elsevier Science, 2007:419-423.
15. Lewis DC, Meyers KM. Studies of platelet-bound and serum platelet-bindable immunoglobulins in dogs with idiopathic thrombocytopenic purpura. Exp Hematol 1996;24:696-701.
16. Balch A, Mackin A. Canine immune-mediated hemolytic anemia: Treatment and prognosis. Compend Contin Educ Vet 2007;29: 230-238.
17. Zen M, Canova M, Campana C, et al. The kaleidoscope of glucocorticoid effects on immune system. Autoimmun Rev 2011;10:305-310.
18. Hearing SD, Norman M, Smyth C, Foy C, Dayan CM. Wide variation in lymphocyte steroid sensitivity among healthy human volunteers. J Clin Endocrinol Metab 1999;84:4149-4154.
19. Yang N, Ray DW, Matthews LC. Current concepts in glucocorticoid resistance. Steroids 2012;77:1041-1049.
20. Bianco D, Hardy RM. Treatment of Evans' syndrome with human intravenous immunoglobulin and leflunomide in a diabetic dog. J Am Anim Hosp Assoc 2009;45:147-150.
21. Colopy SA, Baker TA, Muir P. Efficacy of leflunomide for treatment of immune-mediated polyarthritis in dogs: 14 cases (2006-2008). J Am Vet Med Assoc 2010;236:312-318.
22. Gregory CR, Stewart A, Sturges B, et al. Leflunomide effectively treats naturally occurring immune-mediated and inflammatory diseases of dogs that are unresponsive to conventional therapy. Transplant Proc 1998;30:4143-4148.
23. Piek CJ, van Spil WE, Junius G, Dekker A. Lack of evidence of a beneficial effect of azathioprine in dogs treated with prednisolone for idiopathic immune-mediated hemolytic anemia: A retrospective cohort study. BMC Vet Res 2011;7:1-9.
24. Allison AC. Immunosuppressive drugs: The first 50 years and a glance forward. Immunopharmacology 2000;47:63-83.
25. Kyles AE, Gregory CR, Craigmill AL. Comparison of the in vitro antiproliferative effects of five immunosuppressive drugs on lymphocytes in whole blood from cats. Am J Vet Res 2000;61:906-909.
26. Hadizadeh F, Moallem SA, Jaafari MR, et al. Synthesis and immunomodulation of human lymphocyte proliferation and cytokine (interferon-gamma) production of four novel malonitrilamides. Chem Biol Drug Des 2009;73:668-673.
27. Gregory CR, Taylor NJ, Willits NH, Theilen GH. Response to isoantigens and mitogens in the cat: effects of cyclosporin A. Am J Vet Res 1987;48:126-130.
28. Takaori K, Nio Y, Inoue K, et al. A comparative study on immunosuppressive effects of cyclosporin A and FK 506 on peripheral blood lymphocytes in dogs. Biotherapy 1992;4: 129-137.
29. Williams DL. Lack of effects on lymphocyte function from chronic topical ocular cyclosporine medication: A prospective study. Vet Ophthalmol 2010;13:315-320.
30. Holford NHG. Pharmacokinetics & pharmacodynamics: Rational dosing & the time course of drug action. In: Katzung BG, Masters SB, Trevor AJ, eds. Basic and Clinical Pharmacology. New York, New York: McGraw-Hill Companies, 2012:37-51.
31. Haczku A, Alexander A, Brown P, et al. The effect of dexamethasone, cyclosporine, and rapamycin on T-lymphocyte proliferation in vitro: Comparison of cells from patients with glucocorticoid-sensitive and glucocorticoid-resistant chronic asthma. J Allergy Clin Immunol 1994;93:510-519.
32. Hearing SD, Norman M, Probert CS, Haslam N, Dayan CM. Predicting therapeutic outcome in severe ulcerative colitis by measuring in vitro steroid sensitivity of proliferating peripheral blood lymphocytes. Gut 1999;45:382-388.
33. Matsuda A, Tanaka K, Muto S, et al. A novel NF-kB inhibitor improves glucocorticoid sensitivity of canine neoplastic lymphoid cells by up-regulating expression of glucocorticoid receptors. Res Vet Sci 2010;89:378-382.
34. Matsuda A, Tanaka A, Amagai Y, et al. Glucocorticoid sensitivity depends on expression levels of glucocorticoid receptors in canine neoplastic mast cells. Vet Immunol Immunopathol 2011;144:321-328. Epub 2011 Aug 26.